Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing

Autor: Chen Jianhe, Xuesai Zhang, Lan Deng, Zhenping Zhu, Li Li, Xiao-Qing Meng, Wei Xu, Yun Meng, Kai Li, Le Zhao, Li Meng, Haomin Huang, Gu Changling

Publikováno v: Translational Oncology, Vol 14, Iss 1, Pp 100916-(2021)
Translational Oncology

Highlights • The anti-PD1 x anti-EGFR bispecific antibody (BsAb) exhibited all in-vitro bioactivities comparable to that of the parental mAbs and showed anti-tumor efficacies of each of the two arms on par with the mAbs in-vivo. • The anti-PD1 x

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec9e80e3b13ebeaac857db1f7f67b80
http://www.sciencedirect.com/science/article/pii/S1936523320304083

Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation

Autor: Eckert, F., Gaipl, U.S., Niedermann, G., Hettich, M., Schilbach, K., Huber, S.M., Zips, D.

Publikováno v: Clinical and Translational Radiation Oncology, Vol 2, Iss C, Pp 29-35 (2017)
Clinical and Translational Radiation Oncology

Highlights • Immunotherapy is being established as forth pillar of cancer therapy. • Besides immune checkpoint inhibition several other immunotherapy approaches are tested. • Radiation induces intratumoural changes that might lead to anti-tumou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::98b687621d5d26c091ab801a752811ef
http://www.sciencedirect.com/science/article/pii/S2405630816300428

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Are BiTEs the "missing link" in cancer therapy?

Autor: Suryadevara CM; Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC, USA ; Department of Pathology; Duke University Medical Center ; Durham, NC, USA ; The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center ; Durham, NC, USA., Gedeon PC; Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC, USA ; The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center ; Durham, NC, USA ; Department of Biomedical Engineering; Duke University ; Durham, NC, USA., Sanchez-Perez L; Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC, USA ; The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center ; Durham, NC, USA., Verla T; Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC, USA ; The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center ; Durham, NC, USA., Alvarez-Breckenridge C; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School ; Boston, MA, USA., Choi BD; Department of Neurosurgery; Massachusetts General Hospital and Harvard Medical School ; Boston, MA, USA., Fecci PE; Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC, USA ; The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center ; Durham, NC, USA., Sampson JH; Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC, USA ; Department of Pathology; Duke University Medical Center ; Durham, NC, USA ; The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center ; Durham, NC, USA ; Department of Biomedical Engineering; Duke University ; Durham, NC, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2015 Apr 30; Vol. 4 (6), pp. e1008339. Date of Electronic Publication: 2015 Apr 30 (Print Publication: 2015).

Nanocell targeting using engineered bispecific antibodies.

Autor: Taylor K; a Australian Institute for Bioengineering and Nanotechnology (AIBN) ; University of Queensland, St Lucia ; Queensland , Australia., Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP, Mahler SM

Publikováno v: MAbs [MAbs] 2015; Vol. 7 (1), pp. 53-65.